Program Description
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are distinct subtypes of non-Hodgkin lymphoma (NHL) associated with significant treatment challenges, particularly in relapsed or refractory disease. Bispecific antibodies (BsAbs) have expanded therapeutic options, with recent approvals and emerging evidence supporting their evolving role across treatment lines. Although these agents have broadened treatment options, the emerging evidence positioning BsAbs in earlier lines of therapy raises new questions about treatment sequencing and patient selection. This webinar prepares oncology pharmacists to better understand guideline recommendations by reviewing key approvals and the latest trial data to inform their clinical contributions around the use of BsAbs in DLBCL and FL. With this foundation, oncology pharmacists will be better positioned to support the safe and effective integration of BsAb therapy into NHL care.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: December 3, 2026
Expiration date: February 1, 2027
Time to complete activity: 1.0 hour
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, pharmacists will be able to:
- Describe the patient criteria, approved indications, and step-up dosing schedules of bispecific antibodies (BsAbs) in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
- Analyze key efficacy and safety outcomes from pivotal and emerging clinical trials to guide the use of BsAbs in practice.
- Apply emerging clinical trial data on earlier-line BsAb use in first- and second-line settings to inform treatment sequencing strategies for patients with DLBCL and FL.
James A. Davis, PharmD, BCOP
Clinical Pharmacy Specialist, Malignant Hematology
The Medical University of South Carolina Hollings Cancer Center
Affiliate Assistant Professor
The Medical University of South Carolina College of Pharmacy
Charleston, SC
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number [UAN pending]. The activity is available for CE credit through February 1, 2027.
Obtaining Credit
All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
James A. Davis, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:
• Consultant: BMS, GSK, Janssen
• Speakers Bureau: GSK, Janssen
The staff of Pharmacy Times Continuing Education™ have no relevant financial relationships with ineligible companies.
At least 1 anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s), or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms